Lumeon wins MedTech Breakthrough Award - Gilde Healthcare

Lumeon wins MedTech Breakthrough Award

June 7, 2017

LONDON AND NEW YORK – Lumeon, a leading digital health company, has won the MedTech Breakthrough Award for Best Overall Health Administration Software. The awards recognize the top companies, people, platforms and products in the global health and medical technology market today.

Lumeon’s Care Pathway Management (CPM) platform, that allows providers to automate and orchestrate workflows across the care continuum, impressed the judges with its capability to digitize risk reducing strategies, improve efficiency and scale best practice.

Robbie Hughes, Lumeon’s CEO said, “Alternative payment models are prompting the industry to think differently about the way care is delivered and how we collaboratively manage risk to deliver better quality outcomes. Providers want better visibility into outcomes data across the care continuum, as well as innovative ways of engaging patients and managing healthcare administration. I’m delighted to accept this award as we continue to deliver solutions that are both personalized and scalable.”

The mission of the MedTech Breakthrough Awards is to honor excellence and recognize the innovation, hard work and success in a range of health and medical technology categories. This year’s program attracted more than 2,000 nominations from over 10 different countries throughout the world. All nominations were evaluated by an independent panel of experts within the medical and health industry.

“We are pleased to recognize Lumeon among the MedTech Breakthrough Awards this year,” stated James Johnson, Managing Director at MedTech Breakthrough. “Health administration can be an extremely complex proposition for healthcare providers, taking focus away from the ultimate goal of improving patient care. By automating and simplifying health workflows with software such as Lumeon’s Care Pathway Management platform, we see tremendous benefits for healthcare providers and patients alike. Congratulations to the entire Lumeon team on their industry recognition.”

Gilde Healthcare Adcendo Completes $135 Million Series B to Advance First- in-class ADC Pipeline

Financing led by TCGX, including new investment from TPG, Orbimed Advisors, Venrock Healthcare Capital Partners, Surveyor Capital (a Citadel company), and Logos Capital, with participation from all existing investors Proceeds will be used to support...
November 25, 2024

Gilde Healthcare portfolio company Levicept Presents Positive Phase II Data for Novel Neurotrophin-3 Inhibitor, LEVI-04 at ACR Convergence 2024

Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis, is presenting the results from its positive Phase II trial of LEVI-04 at the American College of Rheumatology's annual...
November 14, 2024

Gilde Healthcare company Noema Pharma Announces First Patients Dosed in Phase 2b Study for Tourette Syndrome

Phase 2b study will evaluate the safety and efficacy of gemlapodect (NOE-105) in patients with Tourette syndrome Noema Pharma AG, a clinical-stage neuroscience-based company, today announced the first patients have been dosed in a global...
October 30, 2024